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Abstract
Objective To provide perinatal mortality and congenital
anomaly rates for babies born to women with type 1 or type 2
diabetes in England, Wales, and Northern Ireland.
Design National population based pregnancy cohort.
Setting 231 maternity units in England, Wales, and Northern
Ireland.
Participants 2359 pregnancies to women with type 1 or type 2
diabetes who delivered between 1 March 2002 and 28 February
2003.
Main outcome measures Stillbirth rates; perinatal and
neonatal mortality; prevalence of congenital anomalies.
Results Of 2359 women with diabetes, 652 had type 2 diabetes
and 1707 had type 1 diabetes. Women with type 2 diabetes were
more likely to come from a Black, Asian, or other ethnic
minority group (type 2, 48.8%; type 1, 9.1%) and from a
deprived area (type 2, 46.3% in most deprived fifth; type 1,
22.8%). Perinatal mortality in babies of women with diabetes
was 31.8/1000 births. Perinatal mortality was comparable in
babies of women with type 1 (31.7/1000 births) and type 2
diabetes (32.3/1000) and was nearly four times higher than that
in the general maternity population. 141 major congenital
anomalies were confirmed in 109 offspring. The prevalence of
major congenital anomaly was 46/1000 births in women with
diabetes (48/1000 births for type 1 diabetes; 43/1000 for type 2
diabetes), more than double that expected. This increase was
driven by anomalies of the nervous system, notably neural tube
defects (4.2-fold), and congenital heart disease (3.4-fold).
Anomalies in 71/109 (65%) offspring were diagnosed
antenatally. Congenital heart disease was diagnosed antenatally
in 23/42 (54.8%) offspring; anomalies other than congenital
heart disease were diagnosed antenatally in 48/67 (71.6%)
offspring.
Conclusion Perinatal mortality and prevalence of congenital
anomalies are high in the babies of women with type 1 or type
2 diabetes. The rates do not seem to differ between the two
types of diabetes.
Introduction
Pregnancy in women with diabetes is associated with an
increased risk of congenital anomaly, perinatal morbidity, and
mortality in their offspring. These risks have been evaluated pre-
dominantly in women with type 1 diabetes.1–4 The demographic
pattern of diabetes is changing; increasing numbers of young
people are being diagnosed as having type 1 diabetes, and the
number of people diagnosed as having type 2 diabetes is
increasing, predominantly among people in Black, Asian, or
other ethnic minority groups.5 6 Regional studies in the United
Kingdom in the 1990s had indicated raised perinatal mortality
among women with diabetes.4 7 8 Responding to this, the
Confidential Enquiry into Maternal and Child Health
(CEMACH) initiated a programme to assess the quality of
maternity care and to examine pregnancy outcomes for women
with diabetes in England, Wales, and Northern Ireland. Further
information on this programme can be found in the CEMACH
report.9 10 Here we present perinatal mortality and congenital
anomaly rates in the offspring of women with type 1 or type 2
diabetes, born between 1 March 2002 and 28 February 2003.
Methods
We defined pre-gestational diabetes as either type 1 or type 2
diabetes that had been diagnosed at least one year before the
woman’s estimated delivery date. We excluded the group, usually
with type 2 diabetes, who present during pregnancy but in whom
the diagnosis cannot be confirmed until after pregnancy. This
ensured as homogenous a group as possible for the evaluation of
mortality.
Health professionals at each maternity unit filled in a notifi-
cation form and questionnaire for every woman who met the
criteria for pre-gestational diabetes who delivered between 1
March 2002 and 28 February 2003 in England, Wales, and
Northern Ireland. The CEMACH data collection included births
to women resident in the Channel Islands and Isle of Man. The
questionnaire covered demographic characteristics, type of
diabetes, glycaemic control measurements, care from pre-
pregnancy to the neonatal period, and outcome details up to day
28 for the baby. CEMACH regional managers coordinated data
collection, validation of data, and entry on to a database.
All health professionals in England,Wales, and Northern Ire-
land are required to take part in confidential inquiry
programmes; 231 units participated, and 2621 pregnancies were
notified during the study period. We report on 2359
pregnancies; we excluded 262 pregnancies that resulted in
miscarriage at less than 20 weeks of gestation or termination of
pregnancy for indications other than congenital anomaly.
Two extra tables are on bmj.com
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Deprivation
We explored the relation between diabetes in pregnancy and
deprivation by applying an index of multiple deprivation score.11
As this measure applies only to England, we excluded women
resident in Wales and Northern Ireland from this exercise.
Perinatal and neonatal mortality
We defined stillbirth as a fetal loss delivered after 24 completed
weeks of gestation, neonatal death as the death of a live birth up
to 28 days after birth, and perinatal death as a stillbirth or post-
natal death up to seven days after birth. We compared perinatal
mortality with national mortality data from the CEMACH 2002
perinatal death notifications and the Office for National
Statistics.12
Congenital anomalies
We collected data on presumed congenital anomalies for live
births antenatally and up to 28 days of life, for fetal losses after 20
completed weeks of gestation, and for terminations of pregnancy
at any gestation. We confirmed the reported diagnoses by
postmortem findings, genetic results, or correspondence. We
coded confirmed anomalies according to the ICD-10 (interna-
tional classification of diseases, 10th revision) and grouped them
according to the classification system used by the European Sur-
veillance of Congenital Anomalies (EUROCAT) (table A on
bmj.com). We excluded minor anomalies (table B on bmj.com).
We calculated the congenital anomaly rate as the number of off-
spring with one or more major anomalies divided by the number
of live births and stillbirths.13 Offspring included fetal losses after
20 weeks’ gestation and terminations of pregnancy at any gesta-
tion.
We compared the observed numbers of major congenital
anomalies in the cohort with expected numbers based on age
specific rates for 2002 reported to EUROCAT, adjusted for the
maternal age distribution of the women in our study (personal
communication, EUROCAT 2005). To allow for the higher
prevalence of neural tube defects in the UK, we also calculated an
expected figure for neural tube defects on the basis of the
EUROCAT data originating only from Wales and six local regis-
tries in England.
We used Stata 8.0 for analyses. We used the Poisson distribu-
tion to obtain exact 95% confidence intervals for the rate and
prevalence ratios.14
Results
All maternity units in England, Wales, and Northern Ireland
delivering care to women with diabetes participated. Although
we had no measure of the completeness of reporting within
individual units, the observed prevalence of 1 per 264 births was
consistent with the expected prevalence of 1 in 250. Of the 2359
pregnancies, 37 were twin pregnancies and two were triplet
pregnancies, resulting in 2400 offspring. Table 1 gives a descrip-
tion of the outcomes according to gestation at delivery.
Maternal characteristics
More than a quarter of the pregnancies were to women with type
2 diabetes (n = 652; 27.6%). Table 2 shows the characteristics of
the women according to type of diabetes. Compared with the
women with type 1 diabetes, women with type 2 diabetes were
older at onset of diabetes (P < 0.001) and at delivery (P < 0.001),
less likely to be primigravid (P < 0.001), and more likely to live in
a deprived area (P < 0.001) and to come from a Black, Asian, or
other ethnic minority group (P < 0.001). The biggest difference
in the prevalence of the two types of diabetes was observed in
women of Pakistani origin (type 2 diabetes 16%; type 1 diabetes
1.4%).
Most women (1606; 68%) had a recorded measurement of
glycaemic control by 13 weeks of pregnancy. Good control,
defined by glycated haemoglobin (HbA1c) of less than 7%, was
achieved by 596 (37%) women. The median HbA1c was 7.9% for
the women whose pregnancies resulted in a congenital anomaly,
8.0% for those with a normally formed stillbirth or neonatal
Table 1 Gestation at delivery by outcome
Gestation at
delivery
(completed
weeks)
Termination of
pregnancy for
congenital anomaly
Late fetal loss or
stillbirth and
normally formed
Late fetal loss or
stillbirth and
congenital anomaly
Neonatal death
and normally
formed
Neonatal death
and congenital
anomaly
Alive at day 28 and
normally formed
Alive at day 28
and congenital
anomaly Total
<20 13 – – – – – – 13
20 to 23 17 12 2 2 0 0 0 33
24 to 27 4 9 1 5 1 17 1 38
28 to 31 0 11 0 1 1 70 5 88
32 to 36 1 19 4 2 6 718 25 775
37 to 40 0 13 2 1 2 1406 24 1448
≥41 0 0 0 0 0 5 0 5
Total 35 64 9 11 10 2216 55 2400
Table 2 Maternal characteristics by type of diabetes. Values are numbers
(percentages) unless stated otherwise
Women with type 1
diabetes (n=1707)
Women with type 2
diabetes (n=652)
Median (IQR) age (years) at onset of
diabetes
15 (9-23) 29 (25-34)
Median (IQR) age (years) at delivery 30 (26-34) 34 (30-37)
Ethnicity:
White 1549 (90.7) 331 (50.8)
Black African 23 (1.4) 47 (7.2)
Black Caribbean 27 (1.6) 33 (5.1)
Black other 4 (0.2) 3 (0.5)
Indian 25 (1.5) 47 (7.2)
Pakistani 24 (1.4) 106 (16.3)
Bangladeshi 7 (0.4) 47 (7.2)
Chinese 1 (0.1) 2 (0.3)
Other 45 (2.6) 33 (5.1)
Not known 2 (0.1) 3 (0.5)
Multiparous 925 (54.2) 495 (75.9)
Deprivation fifth*:
1 (least deprived) 260 (16.7) 40 (6.4)
2 288 (18.5) 66 (10.5)
3 313 (20.1) 81 (12.9)
4 307 (19.7) 145 (23.1)
5 (most deprived) 355 (22.8) 291 (46.3)
Not known 35 (2.2) 5 (0.8)
Resident in Wales or Northern Ireland 149 24
IQR=interquartile range.
*Percentages calculated only for women resident in England.
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death, and 7.4% for those who had a normally formed baby alive
at day 28.
Perinatal mortality
During the study, 63 stillbirths and 22 neonatal deaths occurred.
Two neonatal deaths occurred before 24 weeks’ gestation, and
one neonatal death was a termination occurring between 24 and
27 weeks’ gestation. Table 3 shows the crude stillbirth rates and
perinatal and neonatal mortality according to type of diabetes.
Figures adjusted for maternal age show significantly higher still-
birth rates (4.7 times higher) and perinatal (3.8 times) and
neonatal mortality (2.6 times) in this cohort compared with the
general maternity population in 2002 (table 4).
Of the 63 stillbirths, 52 had no congenital anomaly (table 1).
In terms of weight adjusted for gestation at delivery, parity of
mother, and sex of baby, a higher proportion of singleton
normally formed stillbirths were above the 90th centile (18/31
(58.1%) compared with 1061/2058 (51.6%) of normally formed
singleton babies alive at day 28. This difference was not
statistically significant. The proportion of babies below the 10th
centile was similar—1/31 (3.2%) normally formed singleton still-
births and 58/2058 (2.8%) normally formed singleton babies
alive at day 28.
Congenital anomalies
A total of 141 major congenital anomalies were identified and
confirmed in 109 offspring (table 5). The number of offspring
with more than one major anomaly was 23 (21.1% of offspring
with anomalies). The most common diagnoses were multiple
anomalies of the heart or of the limb, musculoskeletal, and con-
nective tissue system.
The prevalence of major anomalies in the offspring was 46
per 1000 total births. This compares with 21 per 1000 total births
from the EUROCAT data for 2002 (prevalence ratio 2.2, 95%
confidence interval 1.8 to 2.6; P < 0.001). The prevalence of
major anomalies associated with type 1 diabetes was 48 per 1000
total births, and the prevalence associated with type 2 diabetes
was 43 per 1000 total births.
Statistically significant increases were confined to anomalies
of the nervous system (prevalence ratio 2.7, 1.5 to 4.4; P < 0.001)
and congenital heart disease (prevalence ratio 3.4, 2.5 to 4.6;
P < 0.001). The increase in anomalies of the nervous system was
driven by an increase in the observed number of neural tube
defects (prevalence ratio 4.2, 2.0 to 7.8; P < 0.001). The ratio for
neural tube defects determined from the EUROCAT data from
Wales and England only was 3.3 (1.6 to 6.1; P < 0.001). The neu-
ral tube defects were diagnosed antenatally in all 10 offspring.
Anomalies in 71 (65%) of 109 offspring with anomalies were
diagnosed antenatally (23/42 (54.8%) of offspring with congeni-
tal heart disease and 48/67 (71.6%) of offspring with anomalies
other than congenital heart disease) (table 6). Fifty per cent (35/
71) of the anomalies diagnosed antenatally were terminated
(table 1).
Discussion
This large national study details the outcomes of pregnancy for
women with type 1 or type 2 diabetes. Nearly 15 years on from
the St Vincent declaration,15 women with diabetes in England,
Wales, and Northern Ireland continue to have high perinatal
Table 3 Crude stillbirth rate and perinatal and neonatal mortality in births to women with type 1 or type 2 diabetes
Type 1 diabetes (n=1706 live and stillbirths) Type 2 diabetes (n=650 live and stillbirths)
No Rate (95% CI) No Rate (95% CI)
Stillbirth* 44 25.8 (18.3 to 33.3) 19 29.2 (16.3 to 42.2)
Perinatal death* 54 31.7 (23.3 to 40.0) 21 32.3 (18.7 to 45.9)
Neonatal death† 16 9.6 (4.9 to 14.3) 6 9.5 (1.9 to 17.1)
Figures do not include 13 terminations of pregnancy (9 type 1, 4 type 2) before 20 weeks’ gestation and 31 losses (22 type 1, 9 type 2) between 20 weeks’ and 23+6 weeks’ gestation.
*Rate per 1000 live births plus stillbirths.
†Rate per 1000 live births.
Table 4 Maternal age adjusted stillbirth rate and perinatal and neonatal
mortality in births to women with type 1 and type 2 diabetes compared with
national data.
Type 1 and 2 diabetes (n=2356
live and stillbirths)
National
rate* (n=620
841)
Rate ratio (95%
CI)
Number Rate (95% CI)
Stillbirth† 63 26.8 (19.8 to 33.8) 5.7 4.7 (3.7 to 6.0)
Perinatal death† 75 31.8 (24.2 to 39.4) 8.5 3.8 (3.0 to 4.7)
Neonatal death‡ 22 9.3 (5.2 to 13.3) 3.6 2.6 (1.7 to 3.9)
*Source for national data: CEMACH 2002.10
†Rate per 1000 live births plus stillbirths.
‡Rate per 1000 live births.
Table 5 Observed (and expected*) anomalies reported in 2400 offspring to
women with diabetes
Anomalies
Offspring of
women with
type 1 diabetes
Offspring of
women with
type 2
diabetes Total
Standardised
prevalence ratio
(95% CI)
One or more major
anomalies of any
type
81 (37.0) 28 (12.8) 109 (49.8) 2.2 (1.8 to 2.6)
Anomaly system†
Nervous system: 11 (4.1) 4 (1.5) 15 (5.6) 2.7 (1.5 to 4.4)
Neural tube
defects
6 (2.4) 4 (0.9) 10 (2.4) 4.2 (2.0 to 7.8)
Remainder of CNS 5 (1.7) 0 (0.6) 5 (3.0) 1.5 (0.3 to 3.6)
Eye 1 (2.4) 0 (0.9) 1 (1.0) 1.0 (0.1 to 7.0)
Ear 0 (0.7) 0 (0.3) 0 (1.0) –
Congenital heart
disease
33 (8.9) 9 (3.4) 42 (12.3) 3.4 (2.5 to 4.6)
Cleft lip ± palate 0 (1.3) 0 (0.5) 0 (1.8) –
Cleft palate 2 (0.9) 0 (0.3) 2 (1.2) 1.6 (0.2 to 5.9)
Digestive system 1 (2.6) 2 (1.0) 3 (3.5) 0.8 (0.2 to 2.5)
Internal urogenital
system
9 (6.1) 1 (2.3) 10 (8.5) 1.2 (0.6 to 2.2)
External genital
system
3 (2.5) 2 (0.9) 5 (3.4) 1.5 (0.5 to 3.4)
Limb,
musculoskeletal,
and connective
tissue
15 (10.2) 4 (3.7) 19 (13.9) 1.4 (0.8 to 2.1)
Other
non-chromosomal
6 4 10 –
Chromosomal: 4 (7.2) 2 (4.2) 6 (11.4) 0.5 (0.2 to 1.1)
Trisomy 21 2 0 2 –
Other
chromosomal
2 2 4 –
CNS=central nervous system.
*Expected numbers in parentheses based on data from EUROCAT 2002, adjusted for maternal
age.
†Multiple anomalies within groups counted only once; total anomalies thus do not add up to
141.
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mortality rates (31.8/1000 births), three times greater than for
the general maternity population. Perinatal mortality in
European countries and in other UK regional studies of
outcomes of pregnancy for women with diabetes range from
27.8 to 48 per 1000 births.1–4 7 8 16 17
At the time of the St Vincent declaration evidence existed to
show that near normal metabolic control before and around
conception reduced anomaly rates in the pregnancies of women
with diabetes,18 19 and by 1996 this was reinforced by the diabetes
control and complications trial.20 Since then guidance has been
issued on this topic,21 but little success has been achieved in
translating this into practice. Only 37% of women with a
recorded HbA1c test achieved good glycaemic control by the end
of the first trimester. This does not compare well with the Neth-
erlands, where 75% of women with type 1 diabetes achieved
HbA1c of 7% or less in the first trimester.
1 We did our study at the
same time as the national service framework for diabetes delivery
strategy was released,5 and the results will be a reference point
from which to judge the effectiveness of the framework in tack-
ling this public health concern.
Congenital anomalies
The risk of major congenital anomalies in the offspring of
women with diabetes was more than twice that of the general
population. Other studies have shown comparable prevalence
figures for congenital anomalies, ranging from 41 per 1000 to 97
per 1000, although these studies have been based predominantly
on the babies of women with type 1 diabetes.1–3 7 8 16 17 Compari-
sons are limited because of differences in inclusion criteria for
minor anomalies and early pregnancy outcomes.
In our study, the increased risk of anomalies was
predominantly for congenital heart disease (3.4 times higher
risk) and anomalies of the nervous system (2.7 times higher risk).
In particular, the risk of neural tube defects was three to four
times higher than expected. The minimum effective dose of folic
acid needed to reduce this risk is not established, but because of
the increased risk, women with diabetes should take a higher
than usual dose (5 mg) from before conception up to week 12 of
pregnancy.5 21
Antenatal diagnosis of some cardiac conditions decreases the
risk of neonatal mortality.22 Routine ultrasound scanning for
anomalies in the UK has been reported to identify 23% of
cardiac defects.23 Implementing specialist views of the fetal heart
may increase the pick-up rate of cardiac anomalies up to 75%.24
Our study showed that cardiac lesions were the most frequent
anomaly in the offspring of women with diabetes, and 55% were
detected antenatally. Current management of pregnant women
with diabetes in the UK does not routinely include targeted
screening for cardiac defects; this needs to be reviewed.
Type 2 diabetes
In the past decade, type 2 diabetes in pregnancy has emerged as
a growing concern.25 Few population studies have provided peri-
natal mortality and congenital anomaly rates in women with type
2 diabetes diagnosed before pregnancy. Two of the largest such
studies were based on Maori women in New Zealand and
Hispanic women in California and may not be generalisable.26 27
Other studies have included women in whom the diagnosis of
type 2 diabetes was not made until after delivery.26 28–30 Reported
perinatal mortality in these studies ranges from 6 per 1000 to
313 per 1000 births.28 30
Our study is larger than previous studies describing
pregnancy outcomes for women with type 2 diabetes diagnosed
before pregnancy and shows that adverse pregnancy outcomes
for these women are comparable to those for women with type 1
diabetes. Several studies have reported higher perinatal mortal-
ity and congenital anomaly rates in the babies of women with
type 2 diabetes than in the babies of women with type 1 diabetes,
but they were based on relatively small sample sizes.26 29 31–33 Our
study shows no evidence of an increased risk. However, even a
study of this magnitude was underpowered to detect a significant
increase of less than 25% for perinatal mortality and of less than
80% for congenital anomaly, if such increases were present. We
conclude that no evidence exists of major differences in the risks
of perinatal mortality and congenital anomaly in the offspring of
women with type 1 and type 2 diabetes.
Pregnant women with type 2 diabetes were more likely to live
in a deprived area (P < 0.001) or come from an ethnic minority
background (P < 0.001). These factors may be interrelated.
Women with type 2 diabetes often need to change their
treatment to insulin before or during pregnancy. The differences
in cultural background, first language, lifestyle, and medical care
need to be accounted for when considering provision of health
services for preconception care and education in this area. In the
past, type 2 diabetes may have been viewed as a less serious con-
dition than type 1 diabetes and may have been subject to less
vigilant care.34 In view of the increasing prevalence of type 2 dia-
Table 6 Timing of diagnosis and description of the principal anomaly in 109
offspring with major anomaly
Anomalies
Antenatally
diagnosed
(No)
Postnatally
diagnosed
(No) Total (No)
Cardiac anomalies: 23 19
42
Atrioseptal defect – 2
Hypoplastic left heart 5 –
Ventricular septal defect 1 4
Double inlet left ventricle 1 –
Double outlet right ventricle 2 –
Transposition of great arteries 1 3
Pulmonary artery stenosis 2 2
Pulmonary artery atresia with intact
ventricular septum
1 –
Tetralogy of Fallot 3 4
Coarctation of aorta 1 1
Total pulmonary abnormal venous return – 1
Other* 3 1
Unspecified/misclassified 3 1
Limb, musculoskeletal, and connective tissue: 15 2
17
Caudal regression 4 1
Diaphragmatic hernia 2 –
Gastroschisis 2 –
Achondroplasia 1 –
Other limb defects 1 –
Scoliosis 1 –
Prune belly syndrome 1 –
Other anomalies 3 1
Nervous system: 13 2
15Neural tube defects 10 0
Other central nervous system 3 2
Eye – 1 1
Internal urogenital system 8 1 9
External genital system – 4 4
Chromosomal 6 – 6
Others, non-chromosomal 6 4 10
Digestive system – 3 3
Cleft palate – 2 2
Overall 71 38 109
*Ebstein anomaly, isomerism of atrial appendages, malformation of pulmonary artery and of
aorta.
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betes in young adults, raised awareness of the increased risk of
adverse pregnancy outcomes in this group of women is needed.
Conclusion
Women with type 1 diabetes and those with type 2 diabetes both
represent high risk groups during pregnancy. As the incidence of
diagnosed diabetes continues to increase, especially at young
ages, the number of women with diabetes in pregnancy will also
continue to increase. Our study found a threefold increase in
perinatal mortality and a twofold increase in the congenital
anomaly rate in women with diabetes compared with the general
maternity population. Despite evidence since the late 1980s that
good glycaemic control around conception and early pregnancy
can reduce these adverse outcomes, minimal improvement
seems to have occurred, and only a minority of women achieve
good periconceptional glycaemic control.
This study is substantially larger than any previous ones in
describing pregnancy outcomes for women with pre-gestational
type 2 diabetes. It shows that perinatal mortality and congenital
anomaly rates are comparable to those for type 1 diabetes. More
work is needed to elucidate how women with either type of dia-
betes can best be enabled to improve the outcomes of their preg-
nancy.
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What is already known on this topic
Babies born to women with diabetes are known to have
increased risks of perinatal mortality and congenital
anomalies; most studies have focused on type 1 diabetes
Type 2 diabetes is being diagnosed in an increasing number
of women of childbearing age in the UK
What this study adds
The increased risk of anomalies is predominantly
accounted for by congenital heart disease and neural tube
anomalies
Risks of perinatal mortality and congenital anomalies in the
offspring of women with pre-gestational type 2 diabetes are
equivalent to those in the offspring of women with type 1
diabetes
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